Fsip1 Knockout MDA-MB-231 Cell Line

Description

Fsip1 Knockout MDA-MB-231 Cell Line is engineered from human triple-negative breast cancer (TNBC) MDA-MB-231 cells using CRISPR/Cas9 technology to disrupt the Fibrous Sheath Interacting Protein 1 (Fsip1) gene, a structural component involved in cytoskeletal regulation and cellular motility. This knockout model displays impaired migration and invasion while retaining the mesenchymal morphology and aggressive growth of the parental MDA-MB-231 line. It provides a powerful tool for studying cancer metastasis, actin cytoskeleton remodeling, focal adhesion signaling, and tumor microenvironment interactions. Knockout efficiency is validated through genomic PCR, Sanger sequencing, and functional assays confirming reduced motility. Maintained at low passage numbers (<P20) for genetic stability, the cell line has been rigorously tested and confirmed free of HIV-1, HBV, HCV, Syphilis, mycoplasma, fungi, yeast, and bacteria.

Application

• FOR RESEARCH USE ONLY
  

• The Fsip1 Knockout MDA-MB-231 Cell Line is a specialized model for studying breast cancer metastasis and cytoskeletal dynamics. This engineered system enables investigation of Fsip1’s role in cell motility and invasion through extracellular matrix remodeling. Researchers utilize this knockout line to examine disrupted pseudopod formation and altered migratory behavior in triple-negative breast cancer. The cell line provides a controlled platform for screening anti-metastatic compounds and developing targeted therapies for aggressive breast carcinomas.